Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
1.090
-0.020 (-1.81%)
Jul 6, 2026, 12:47 PM EDT - Market open
Artelo Biosciences Employees
Artelo Biosciences had 7 employees as of December 31, 2025. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change
1
Growth
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,923,571
Market Cap
3.80M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% |
| Jun 30, 2025 | 5 | 0 | - |
| Mar 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 6 | 0 | - |
| Sep 30, 2024 | 5 | 0 | - |
| Jun 30, 2024 | 5 | 0 | - |
| Mar 31, 2024 | 5 | 0 | - |
| Dec 31, 2023 | 6 | -1 | -14.29% |
| Sep 30, 2023 | 5 | 1 | 25.00% |
| Jun 30, 2023 | 5 | 1 | 25.00% |
| Mar 31, 2023 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 7 | 2 | 40.00% |
| Sep 30, 2022 | 4 | -1 | -20.00% |
| Jun 30, 2022 | 4 | - | - |
| Mar 31, 2022 | 4 | - | - |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GeoVax Labs | 19 |
| Decoy Therapeutics | 11 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Galmed Pharmaceuticals | 6 |
| Alzamend Neuro | 6 |
| Creative Medical Technology Holdings | 4 |
| Propanc Biopharma | 2 |
ARTL News
- 4 days ago - Artelo Biosciences Proxy statement: Proxy filing - Filings
- 5 days ago - Artelo Biosciences presents preclinical pain data for ART26.12 - TheFly
- 5 days ago - Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury - GlobeNewsWire
- 6 days ago - Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 - GlobeNewsWire
- 7 days ago - Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 - GlobeNewsWire
- 14 days ago - Artelo Biosciences Proxy statement: Proxy filing - Filings
- 26 days ago - Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Proxy statement: Proxy filing - Filings